Characterizing "adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop

Toxicologic Pathology

Volumn 44, Issue 6, 2016, Pages 810-824

  Palazzi, Xavier ^a   Burkhardt, John E ^b   Caplain, Henri ^a   Dellarco, Vicki ^c   Fant, Pierluigi ^d   Foster, John R ^e   Francke, Sabine ^f   Germann, Paul ^g   Gröters, Sibylle ^h   Harada, Takanori ⁱ   Harleman, Johannes ^j   Inui, Kosei ^k   Kaufmann, Wolfgang ^l   Lenz, Barbara ^m   Nagai, Hirofumi ⁿ   Pohlmeyer Esch, Gabriele ^o   Schulte, Agnes ^p   Skydsgaard, Mikala ^q   Tomlinson, Lindsay ^b   Wood, Charles E ^r   Yoshida, Midori ^s   more..

^a SANOFI   (France)

^b PFIZER INC   (United States)

^c Independent Consultant   (United States)

^d A Charles River Company   (France)

^e ToxPath Sciences Ltd   (United Kingdom)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g ABBVIE INC   (United States)

^h BASF SE   (Germany)

ⁱ INSTITUTE OF ENVIRONMENTAL TOXICOLOGY   (Japan)

^j Fresenius Kabi Deutschland GmbH   (Germany)

^k ISHIHARA SANGYO KAISHA LTD   (Japan)

^l MERCK KGAA   (Germany)

^m F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁿ TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^o KALEIDIS Consultancy in Histopathology   (France)

^p FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^q NOVO NORDISK A S   (Denmark)

^r U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^s Food Safety Commission of Japan   (Japan)

more..

Author keywords

adverse effect; adversity; hazard identification; LOAEL; NOAEL; toxicologic pathology

Indexed keywords

ENVIRONMENTAL CHEMICAL;

ADAPTIVE BEHAVIOR; ENVIRONMENTAL EXPOSURE; EUROPEAN SOCIETY OF TOXICOLOGIC PATHOLOGY; GROWTH CURVE; HUMAN; MORPHOLOGY; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PATHOLOGY; PHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICOLOGICAL PARAMETERS; TOXICOLOGY; WORKSHOP; ADVERSE DRUG REACTION; ANIMAL; CLASSIFICATION; STANDARDS;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GUIDELINES AS TOPIC; HUMANS; RISK ASSESSMENT; TOXICOLOGICAL PHENOMENA; TOXICOLOGY;

EID: 84979695783     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623316642527     Document Type: Review

References (46)

1. Ankley G. T., Bennett R. S., Erickson R. J., Hoff D. J., Hornung M. W., Johnson R. D., Mount D. R., Nichols J. W., Russom C. L., Schmieder P. K., Serrrano J. A., Tietge J. E., Villeneuve D. L., (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 29, 730-41.
2. Becker R. A., Ankley G. T., Edwards S. W., Kennedy S. W., Linkov I., Meek B., Sachana M., Segner H., Van Der Burg B., Villeneuve D. L., Watanabe H., Barton-Maclaren T. S., (2015). Increasing scientific confidence in adverse outcome pathways: Application of tailored Bradford-Hill considerations for evaluating weight of evidence. Regul Toxicol Pharmacol 72, 514-37.
3. Bodié K., Decker J. H., (2014). Incidental histopathological findings in hearts of control beagle dogs in toxicity studies. Toxicol Pathol 42, 997-1003.
4. Boekelheide K., Schuppe-Koistinen I., (2012). SOT/EUROTOX debate: Biomarkers from blood and urine will replace traditional histopathological evaluation to determine adverse responses. Toxicol Sci 129, 249-55.
5. Boobis A. R., Cohen S. M., Dellarco V., McGregor D., Meek M. E., Vickers C., Willcocks D., Farland W., (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36, 781-92.
6. Boobis A. R., Doe J. E., Heinrich-Hirsch B., Meek M. E., Munn S., Ruchirawat M., Schlatter J., Seed J., Vickers C., (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38, 87-96.
7. Burger G. T., Renne R. A., Sagartz J. W., Ayres P. H., Coggins C. R., Mosberg A. T., Hayes A. W., (1989). Histologic changes in the respiratory tract induced by inhalation of xenobiotics: Physiologic adaptation or toxicity? Toxicol Appl Pharmacol 101, 521-42.
8. Clemo F. A. S., Evering W. E., Snyder P. W., Albassam M. A., (2003). Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol Pathol 31, 25-31.
9. CIOMS (Council for International Organizations of Medical Sciences VI). (2005). Management of safety information from clinical trials. Accessed December 2, 2015. http://www.cioms.ch/publications/blurbs/management-of-safety-information.htm.
10. Dinauer M. C., Coates T. D., (2005). Disorders of phagocyte function and number. In Hematology Basic Principles and Practice (Hoffman R., Benz E. J., Shattil S. J., Furie B., Cohen H. J., Silberstein L. E., McGlave P., eds.), pp. 787-829. Elsevier Churchill Livingston, Philadelphia, PA.
11. Dorato M. A., Engelhardt J. A., (2005). The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s). Regul Toxicol Pharmacol 42, 265-74.
12. ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals). (2002). Recognition of, and differentiation between, adverse and non-adverse effects in toxicology studies. Technical Report No. 85, ISSN-0773-6347-85, European Centre for Ecotoxicology and Toxicology of Chemicals, Brussels, Belgium.
13. ECHA (European Chemical Agency). (2015). Introductory guidance on the CLP regulation version 2.0. Accessed December 2, 2015. http://echa.europa.eu/documents/10162/13562/clp-introductory-en.pdf.
14. EMA (European Medicines Agency). (2007). Guideline on strategies to identify and mitigate risks for first-in human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07. Accessed December 2, 2015. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002988.pdf.
15. Ettinger S. J., Barrett K. A., (1995). Weakness and syncope. In Textbook of Veterinary Internal Medicine (Ettinger S. J., Feldman E. C., eds.), pp. 50-57. W. B. Saunders, Philadelphia, PA.
16. Everds N. E., Snyder P. W., Bailey K. L., Bolon B., Creasy D. M., Foley G. L., Rosol T. J., Sellers T., (2013). Interpreting stress responses during routine toxicity studies: A review of the biology, impact, and assessment. Toxicol Pathol 41, 560-614.
17. Hailey J. R., Nold J. B., Brown R. H., Cullen J. M., Holder J. C., Jordan H. L., Ennulat D., Miller R. T., (2014). Biliary proliferative lesions in the Sprague-Dawley rat: Adverse/non-adverse. Toxicol Pathol 42, 844-54.
18. Hall A. P., Elcombe C. R., Foster J. R., Harada T., Kaufmann W., Knippel A., Küttler K., Malarkey D. E., Maronpot R. R., Nishikawa A., Nolte T., Schulte A., Strauss V., York M. J., (2012). Liver hypertrophy: A review of adaptive (adverse and non-adverse) changes-Conclusions from the 3rd International ESTP Expert Workshop. Toxicol Pathol 40, 971-94.
19. Hard G. C., Khan K. N., (2004). A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment. Toxicol Pathol 32, 171-80.
20. Hayashi S., Taketa Y., Inoue K., Takahashi M., Matsuo S., Irie K., Watanabe G., Yoshida M., (2013). Effects of piperonyl butoxide on the female reproductive tract in rats. J Toxicol Sci 38, 891-902.
21. Holsapple M. P., Wallace K. B., (2008). Dose response considerations in risk assessment: An overview of recent ILSI activities. Toxicol Lett 180, 85-92.
22. Johnson D. E., Thompson B., Calia F. M., (1985). Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. Antimicrob Agents Chemother 28, 735-39.
23. Kaufmann W., Bader R., Ernst H., Harada T., Hardisty J., Kittel B., Kolling A., Pino M., Renne R., Rittinghausen S., Schulte A., Wöhrmann T., Rosenbruch M., (2009). 1st International ESTP expert workshop: "Larynx squamous metaplasia." A re-consideration of morphology and diagnostic approaches in rodent studies and its relevance for human risk assessment. Exp Toxicol Pathol 61, 591-603.
24. Keenan C., Elmore S., Francke-Carroll S., Kemp R., Kerlin R., Peddada S., Pletcher J., Rinke M., Schmidt S. P., Taylor I., Wolf D. C., (2009). Best practices for use of historical control data of proliferative rodent lesions. Toxicol Pathol 37, 679-93.
25. Keller D. A., Juberg D. R., Catlin N., Farland W. H., Hess F. G., Wolf D. C., Doerrer N. G., (2012). Identification and characterization of adverse effects in 21st century toxicology. Toxicol Sci 126, 291-97.
26. Kerlin R., Bolon B., Burkhardt J. E., Francke S., Greaves P., Meador V., Popp J., (2016). Scientific and regulatory policy committee: Recommended ("Best") practices for determining, communicating, and using adverse effect data from nonclinical studies. Toxicol Pathol 44, 147-62.
27. Lewis R. W., Billington R., Debryune E., Gamer A., Lang B., Carpanini F., (2002). Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol 30, 66-74.
28. Long G. G., Hardisty J. F., (2012). Regulatory forum opinion piece: Thresholds in toxicologic pathology. Toxicol Pathol 40, 1079-81.
29. Maronpot R. R., Yoshizawa K., Nyska A., Harada T., Flake G., Mueller G., Singh B., Ward J. M., (2010). Hepatic enzyme induction: Histopathology. Toxicol Pathol 38, 776-95.
30. Marrs T. C., Bright J. E., Woodman A. C., (1987). Species differences in methaemoglobin production after addition of 4-dimethylaminophenol, a cyanide antidote, to blood in vitro: A comparative study. Comp Biochem Physiol B 86, 141-48.
31. Meek M. E., Boobis A., Cote I., Dellarco V., Fotakis G., Munn S., Seed J., Vickers C., (2014). New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol 34, 1-18.
32. MHLW (Ministry of Health, Labour and Welfare). (2012). Guidance for establishing safety in first-in-human studies during drug development. Accessed December 2, 2015. http://www.cobridge.com/wp-content/uploads/2012/09/jimurenraku-20120418.pdf.
33. Ness P. M., Kruskall M. S., (2005). Principles of red blood cell transfusion. In Hematology Basic Principles and Practice (Hoffman R., Benz E. J., Shattil S. J., Furie B., Cohen H. J., Silberstein L. E., McGlave P., eds.), pp. 2423-32. Elsevier Churchill Livingston, Philadelphia, PA.
34. Nielsen G. D., Ovrebø S., (2008). Background, approaches and recent trends for setting health-based occupational exposure limits: A mini review. Regul Toxicol Pharmacol 51, 253-69.
35. Nikula K. J., McCartney J. E., McGovern T., Miller G. K., Odin M., Pino M. V., Matthew D., (2014). STP position paper: Interpreting the significance of increased alveolar macrophages in rodents following inhalation of pharmaceutical materials. Toxicol Pathol 42, 472-86.
36. OECD (Organisation of Economic Co-operation and Development). (2013). Guidance document on developing and assessing adverse outcome pathways. In Series on Testing and Assessment No. 184. ENV/JM/MONO(2013)6. Paris, France. Accessed March 25, 2016. http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=env/jm/mono (2013) 6&doclanguage=en.
37. Perry R., Farris G., Bienvenu J. G., Dean C., Foley G., Mahrt C., Short B., (2013). Society of Toxicologic Pathology position paper on best practices on recovery studies: The role of the anatomic pathologist. Toxicol Pathol 41, 1159-69.
38. Rao G. N., Edmondson J., Elwell M. R., (1993). Influence of dietary protein concentration on severity of nephropathy in Fischer-344 (F-344/N) rats. Toxicol Pathol 21, 353-61.
39. Russell K., (2010). Platelet kinetics and laboratory evaluation of thrombocytopenia. In Schalm's Veterinary Hematology (Weiss D. J., Wardrop J., eds.), pp. 576-85. Wiley Blackwell, Ames, IA.
40. Shackelford C., Long G., Wolf J., Okerberg C., Herbert R., (2002). Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 30, 93-96.
41. Stansell K., Marvelli M., Wiener J. B., (2005). "Adverse effects" and similar terms in US law. Report for the dose response specialty group of the Society for Risk Analysis (SRA). Accessed December 2, 2015. http://www.sra.org/sites/default/files/u35/Adverse-Effects-Report.pdf.
42. U.S. EPA (U.S. Environmental Protection Agency). (2002). Hepatocellular hypertrophy-Technical report. HED guidance document #G0201. Prepared by The HED Toxicology Science Advisory Council, Office of Pesticide Programs, US EPA. Accessed December 2, 2015. http://hero.epa.gov/index.cfm?action=reference.details&reference-id=625713.
43. U.S. FDA (U.S. Food and Drug Administration). (2005). Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Accessed December 2, 2015. http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
44. WHO Core Assessment Group on Pesticide Residues. (2015). Pesticide residues in food. WHO/HSE/FOS/2015.1. Accessed January 4, 2016. http://www.who.int/foodsafety/areas-work/chemical-risks/jmpr-Guidance-Document-FINAL.pdf.
45. Williams G. M., Iatropoulos M. J., (2007). Alteration of liver cell function and proliferation: Differentiation between adaptation and toxicity. Toxicol Pathol 30, 41-53.
46. Working P. K., (1988). Male reproductive toxicology: Comparison of the human to animal models. Environ Health Perspect 77, 37-44.